|Bid||53.26 x 46200|
|Ask||53.99 x 2000|
|Day's Range||99.83 - 101.20|
|52 Week Range||67.50 - 129.85|
|PE Ratio (TTM)||38.30|
|Forward Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|
IPSEN (IPSEY) seems well-positioned for future earnings growth and it is seeing rising earnings estimates as well, coupled with a solid Zacks Rank.
Commercial Vehicle Group, MTS Systems, Ipsen, AXA and Arkema highlighted as Zacks Bull and Bear of the Day
The CAC 40 index achieved its highest close since Aug 2015 as investors welcomed the prospect of Macron becoming France's next president.
The U.S. Food and Drug Administration said on Tuesday it had approved Lexicon Pharmaceuticals Inc's oral drug to treat carcinoid syndrome diarrhea, a condition that develops in patients with gastrointestinal tumors. The drug, Xermelo or telotristat ethyl, was tested on patients unable to tolerate somatostatin analog therapy (SSA) — the standard-of-care treatment for carcinoid syndrome diarrhea from companies such as Novartis AG and Ipsen SA .
Drugmaker Sanofi is close to selling some over-the-counter products to Ipsen SA, in a deal that could be valued at nearly 100 million euros , Bloomberg reported. The deal between the French drugmakers ...
The deal would give Merrimack the resources to fund the development of three new compounds targeting pancreatic, lung, and other types of cancers. It would boost Ipsen's portfolio, which has traditionally focused on endocrinology. Ipsen will pay $575 million at the closing of the deal and up to $450 million more, contingent on some approvals for Onivyde in the United States.